Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Scusami who wrote (13959)	1/30/1998 1:09:00 PM
From: Andreas Helke	Read Replies (1) \| Respond to of 32384

Henry did not get it right either. The use of an inhaler should be positive for Eli Lillys insulin sales because it will most likely increase the overall market for insulin. You need more because the method is less efficient and probably a bigger part of the type II diabetes population will accept insulin treatment if they can inhale instead of inject. There is of course a certain danger that the market for oral diabetes medicaments will get smaller if more people use insulin. Andreas